Productive infection of T lymphocytes with human immunodeficiency virus type 1 (HIV-1) is accompanied by a diminution of surface CD4 receptors. Treatment of chronically HIV-1-infected CD4-negative T cells in vitro with the Tat antagonist Ro 5-3335 resulted in a drug dose-dependent decrease in virus protein production and a reciprocal increase in surface CD4 display. The drug-treated cells remained viable, showed significantly reduced levels of the full-length and spliced HIV-1 mRNAs as detected by Northern (RNA) blot hybridization, and maintained integrated HIV-1 DNA. In immunoprecipitation studies with drug-treated cells, the levels of free 55-kDa CD4 protein increased and gpl60 complexed with CD4 decreased in amount. These results show for the first time that certain cytopathogenic effects of chronic lIV-1 infection can be reversed by suppressing virus expression.
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CD4 is a member of the immunoglobulin superfamily which is required for the immunologic function of helper/ inducer T lymphocytes (6, 20) and also serves as the receptor for human immunodeficiency virus type 1 (HIV-1) (9, 18, 19) . HIV-1 infection of T cells or monocytes in vitro usually results in a loss of surface CD4 (11) (12) (13) 21) . In effect, HIV-1-infected helper/inducer T cells incur damage at two levels: they lose immunologic signal molecules (that is, CD4), and they may perish as a result of viral replication. Both these effects can contribute to the development of immunodeficiency and AIDS (24) . The mechanisms responsible for CD4 downmodulation are not fully understood, but initial infection kinetics studies suggested a correlation between the CD4 decline and the increased expression of HIV-1 RNA and proteins (12, 27) . HIV-1 infection has little effect on the steady-state levels of CD4 mRNA (11-13, 16, 17, 27) , indicating that CD4 downmodulation by HIV-1 is posttranscriptional. This notion is substantiated by reports showing that cells productively infected with HIV-1 accumulate intracellular complexes of viral gpl60 glycoproteins and newly synthesized CD4 (11-13, 16, 17, 27) , formation of which could prevent CD4 transport to the plasma membrane (1, 8, 15) . Induction of latent HIV-1 in vitro causes rapid downmodulation of surface CD4, consistent with increased synthesis of viral gpl60 polyprotein and the appearance of intracellular CD4-gpl6O complexes (3) . Taken together, these results suggest an inverse correlation between surface CD4 levels and HIV-1 expression. In this work, we tested whether the loss of surface CD4 in HIV-1-infected T cells in vitro can be reversed by inhibiting the expression of the extent HIV-1 genome. We report that treatment of chronically infected, CD4-negative T cells with the recently described HIV-1 Tat antagonist diminished the production of HIV-1 RNA and proteins and consequently increased the intracellular levels of free CD4 and partially restored surface CD4 display. Ro 5-3335 dose-response experiment using CR10/N1T cells, derivatives of CR10 cells (4) chronically and productively infected with HIV-1 strain NlT (25) , are summarized in Table 1 . As previously demonstrated, these cells do not display surface CD4 receptors (4) and exhibit lower levels of CD4 protein immunoprecipitable by OKT4A antibody than uninfected CR10 cells (27) . CR10/NiT cells were washed, supplemented with various doses of Ro 5-3335, and cultured for 6 days under standard conditions. Cell viability was determined by trypan blue exclusion, and HIV-1 antigens were detected either by indirect immunofluorescence (IF) staining of cell smears fixed in acetone (4) or by measuring the levels of HIV-1 p24 capsid proteins in cell lysates (10 x 106 cells per ml) with the Coulter HIV-1 Ag Assay (Coulter Immunology, Hialeah, Fla.), as described previously (29) . Surface CD4 was analyzed by flow cytometry in an Epics C instrument using monoclonal T4 antibody conjugated with rhodamine B isothiocyanate (Coulter Immunology). The T4 antibody does not compete for the gpl20 binding site on CD4.
In agreement with our recent study (14) , incubation of CR10/NiT cells with Ro 5-3335 for 6 days resulted in a drug dose-dependent decline in the production of HIV-1 p24 core proteins from over 2,000 ng/106 cells in the absence of drug to about 30 ng/106 cells in the presence of 5 ,uM Ro 5-3335 (Table 1 ). Significant reduction in the expression of intracellular viral antigens detected by IF staining, from 66 to 2% IF-positive cells, respectively, was also observed ( Table 1) . The median dose-response concentration (50% inhibitory concentration) for Ro 5-3335, extrapolated from p24 data in Table 1 , is about 0.5 ,uM, which is within the 0.1 to 1 pM range reported for a variety of target cells infected with various HIV-1 strains (14) . Dideoxycytidine, a reverse transcription inhibitor, had no effect on HIV-1 replication in CR10/NiT cells (data not shown). Removal of Ro 5-3335 after 6 days of incubation at a 10 ,uM concentration resulted in rapid restoration of HIV-1 production ( (4) p,M Ro 5-3335 for 6 days essentially as described were then analyzed in parallel for HIV-1 ( Fig.  sion (Fig. 2) (14) .
fe absence ofthe drug.
To evaluate the status of proviral DNA, total cellular DNAs from untreated and drug-treated CR10/NiT cells, shown in Fig. 1A and B, were analyzed by Southern blot hybridization (Fig. 1D) . No difference either in relative ng HIV-1 expreslevels of HIV-1 DNA or in the respective endonuclease I cells (14) .
digestion patterns (Fig. 1D) 2% sodium deoxycholate, and 0.5% Nonidet P-40. Cell lysates were incubated with Leu3A bound to protein G-Sepharose (Pharmacia), and the conjugates were analyzed by electrophoresis on an 8% polyacrylamide gel (27) . The Leu3A precipitate from Ro 5-3335-treated CR10/NiT cells contained clearly detectable 55-kDa CD4 protein (Fig. 2B ), in accord with partial restoration of surface CD4 display in these cells as detected by flow cytometry (Fig. 2C) . In contrast (and consistent with our previous study on CD4 downmodulation [27] ), the Leu3A precipitate from extracts of untreated CR10/NiT cells contained a barely detectable 55-kDa band (Fig. 2B ). This indicated a low level of free CD4 in these cells and coincided with the lack of CD4 display on the cell surface (Fig. 2C) .
A more definitive demonstration of the role of intracellular CD4-gpl60 complexes in both the diminution (in CR10/N1T cells) and restoration (in Tat antagonist-treated CR10/NiT cells) of surface CD4 expression was obtained by immunoprecipitation with T4-4, a rabbit polyclonal antiserum to CD4 which precipitates CD4-gpl60 complexes (10) . CR10/N1T and control CR10 cells were treated with Ro 5-3335 as described above; HIV-1 expression in CR10/NiT cells incubated in the presence of 10 ,uM Ro 5-3335 declined from 92 to 2% IF-positive cells (Fig. 3, third beled with 35S-amino acids and lysed, and the cell lysates were used for immunoprecipitation with the T4-4 anti-CD4 antiserum (AIDS Research and Reference Reagent Program, Rockville, Md.) as described for Fig. 2 above. In extracts of untreated CR10/NiT cells, the T4-4 antibody coprecipitated CD4 and gp160 (Fig. 3, third lane from left) , demonstrating the presence of CD4-gpl60 complexes in these chronically HIV-1-infected cells. In contrast, undetectable amounts of labeled gpl60 were coprecipitated in CR10/NiT cells treated with 10 ,uM drug and a significant reduction in gpl60 coprecipitation was observed in cells treated with an intermediate dose of the drug, which was partially effective in reducing HIV-1 expression (Fig. 3) . Control rabbit serum did not precipitate any proteins in the 55-or 160-kDa regions (results not shown). These data indicate that the restoration of surface CD4 expression in Tat inhibitor-treated HIV-1-infected cells is due to the reduction in the levels of CD4-gpl60 intracellular complexes, making CD4 available for display on the cell surface. It should be noted that the surface CD4 redisplay in the presence of Tat inhibitor did not attain the levels observed in uninfected cells (Table 1 ; Fig.  1 ). This can be attributed to an incomplete extinction of HIV-1 expression in chronically infected cells by (Table 1 ; Fig. 1 and 3) , as is also indicated by the drug dose dependence of the reduction in CD4-gp160 complex formation (Fig. 3) .
We have shown that the reduction of HIV-1 expression in chronically infected, CD4-negative cells by treatment with a Tat antagonist permits partial redisplay of surface CD4 receptors. Our results indicate that this effect is due to a decrease in the amount of CD4 complexed with gp160 and a consequent elevation in the level of free (Leu3A-reactive) CD4. The Tat antagonist does not affect the steady-state levels of CD4 mRNA, indicating that the fluctuations in CD4 expression described here are posttranscriptional. Our data are consistent with previous reports that indicated a correlation among surface CD4 display, relative levels of HIV-1 expression, and formation of intracellular CD4-gpl6O complexes (1, 3, 8, 12, 13, 15-17, 21, 27) . In vivo, HIV-1 is most often found in CD4-positive T cells, and it has been postulated that most of these cells carry latent or poorly expressed J. VIROL. This work was supported in part by grant Al 27397 for a National Cooperative Drug Discovery Group from NIH-NIAID and by a grant from the Pediatric AIDS Foundation.
